Table 4.

Univariate and Multivariate Competing Risks Analyses of Predictors of Dropout in the Down-staging group

Univariate Analysis
Predictor Variables	Sub-Hazard ratio (95% CI)	P-value
Diagnosis of Liver Disease
HBV (vs. HCV)	1.29 (0.60–2.74)	0.51
Others (vs. HCV)	2.12 (1.04–4.28)	0.04
Child’s class cirrhosis
B (vs. A)	1.82 (0.96–3.47)	0.07
C (vs. A)	1.66 (0.61–4.51)	0.32
AFP
≥ 10 (vs. < 10)	0.99 (0.54–1.83)	0.98
≥ 100 (vs. < 100)	1.68 (0.89–3.16)	0.11
≥ 300 (vs. < 300)	1.91 (0.96–3.8)	0.07
≥ 400 (vs. < 400)	1.54 (0.75–3.18)	0.24
≥ 500 (vs. < 500)	1.56 (0.72–3.35)	0.26
≥ 1000 (vs. < 1000)	2.38 (1.06–5.35)	0.04
Types of LRT
TACE (vs. RFA)	1.26 (0.41–3.9)	0.68
Combination Treatment (vs. RFA)	0.94 (0.30–2.94)	0.92
Number of lesions
2–3 (vs. 1)	1.06 (0.51–2.18)	0.88
4–5 (vs. 1)	1.53 (0.62–3.76)	0.35
Diameter of largest lesion (per 1 cm increase)	1.04 (0.84–1.28)	0.69
Multivariate Analysis:
Predictor Variables	Hazard ratio (95% CI)	P-value
Child’s class cirrhosis
B (vs. A)	2.19 (1.04–4.64)	0.04
C (vs. A)	1.66 (0.61–4.51)	0.31
AFP ≥ 1000 ng/mL	2.42 (1.16–5.05)	0.02

Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; LRT, local regional therapy; TACE, transarterial chemoembolization; RFA, radiofrequency ablation.